Nektar Therapeutics grants 16,500 stock options

Nektar Therapeutics reported that Chief R&D Officer Jonathan Zalevsky received a grant of stock options covering 16,500 shares of common stock at an exercise price of $15.1500 per share, expiring on 2032-12-12.

Rhea-AI Filing Summary

Nektar Therapeutics reported that Chief R&D Officer Jonathan Zalevsky received a grant of stock options covering 16,500 shares of common stock at an exercise price of $15.1500 per share, expiring on 2032-12-12. These options were granted on December 13, 2024 under the 2017 Amended and Restated Performance Incentive Plan with both performance-based and time-based vesting. The Organization and Compensation Committee determined on July 23, 2026 that the performance condition was satisfied, and the options vested on July 24, 2026, subject to continued monthly pro-rata time-based vesting over five years from the grant date.

Insider Trade Summary

Grant/Award: 16,500 shares

Grant/Award 1 txn

Insider Zalevsky Jonathan

Role Chief R&D Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option F1, F2	16,500	$0.00	$0.00

Holdings After Transaction: Stock Option — 16,500 contracts (Direct)

Footnotes (2)

1. F1. These stock options were granted on December 13, 2024 under the 2017 Amended and Restated Performance Incentive Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of five years from the date of grant.
2. F2. The Organization and Compensation Committee of the Board of Directors of the Issuer determined on July 23, 2026 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on July 24, 2026 (subject to remaining time-based vesting requirements).

Key Figures

Stock options granted: 16500.0000 shares Exercise price: $15.1500 per share Underlying common shares: 16500.0000 shares +5 more

8 metrics

Stock options granted 16500.0000 shares Grant to Chief R&D Officer Jonathan Zalevsky

Exercise price $15.1500 per share Conversion or exercise price of the stock options

Underlying common shares 16500.0000 shares Common stock underlying the reported stock options

Expiration date 2032-12-12 Expiration of the reported stock options

Grant date December 13, 2024 Original grant date under the 2017 Amended and Restated Performance Incentive Plan

Performance condition determination July 23, 2026 Date Committee determined performance-based vesting requirement was satisfied

Vesting commencement linked date July 24, 2026 Date on which the options vested subject to remaining time-based vesting

Time-based vesting period 5 years Monthly pro-rata vesting over five years from December 13, 2024

Key Terms

performance-based vesting, time-based vesting, 2017 Amended and Restated Performance Incentive Plan, Organization and Compensation Committee

4 terms

performance-based vesting financial

"were subject to both performance-based and time-based vesting requirements"

time-based vesting financial

"The time-based vesting is on a monthly pro-rata basis over a period of five years"

Time-based vesting is a schedule that gives employees or contractors ownership of granted stock or options gradually as they remain with a company, like unlocking rewards in a loyalty program the longer you stick around. For investors, it matters because it affects future share supply, management incentives and staff retention — all of which can influence company performance and dilution of existing shareholders.

2017 Amended and Restated Performance Incentive Plan financial

"These stock options were granted on December 13, 2024 under the 2017 Amended and Restated Performance Incentive Plan"

Organization and Compensation Committee financial

"The Organization and Compensation Committee of the Board of Directors of the Issuer determined"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Nektar Therapeutics (NKTR) report for Jonathan Zalevsky?

Nektar Therapeutics reported a grant of stock options to Chief R&D Officer Jonathan Zalevsky covering 16,500 shares of common stock. The options were granted under the 2017 Amended and Restated Performance Incentive Plan with performance-based and time-based vesting conditions.

How many stock options were granted to the NKTR Chief R&D Officer and at what exercise price?

Jonathan Zalevsky received 16,500.0000 stock options with an exercise price of $15.1500 per share. These options relate to an equivalent number of shares of Nektar Therapeutics common stock as the underlying security upon exercise, if vesting conditions are met.

What are the vesting terms of the Nektar Therapeutics (NKTR) stock options granted on December 13, 2024?

The options granted on December 13, 2024 vest based on both performance-based and time-based requirements. Time-based vesting occurs on a monthly pro-rata basis over five years from the grant date, subject to the satisfied performance condition.

When was the performance-based vesting condition satisfied for the NKTR stock options?

The Organization and Compensation Committee determined on July 23, 2026 that the performance-based vesting requirement was satisfied. As a result, the stock options vested on July 24, 2026, while remaining subject to ongoing time-based vesting requirements over the five-year schedule.

What is the expiration date of the Nektar Therapeutics (NKTR) stock options granted to Jonathan Zalevsky?

The reported stock options held by Jonathan Zalevsky expire on 2032-12-12. After this expiration date, any unexercised portion of the 16,500.0000 options at the $15.1500 exercise price will no longer be exercisable under the plan’s terms.

Were the NKTR stock option transactions reported under a Rule 10b5-1 trading plan?

The report indicates the Rule 10b5-1 trading plan affirmation box was not checked. This means the company did not identify this stock option grant and vesting event as occurring pursuant to an affirmatively disclosed Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/24/2026 - 06:35 PM Accepted by SEC EDGAR 07/24/2026 - 06:35 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zalevsky Jonathan

(Last) (First) (Middle)

C/O NEKTAR THERAPEUTICS

455 MISSION BAY BLVD SOUTH

(Street)

SAN FRANCISCO CALIFORNIA 94158

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEKTAR THERAPEUTICS [ NKTR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief R&D Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option(1)	$15.15	07/24/2026		A		16,500		(2)	12/12/2032	Common Stock	16,500	$0.00	16,500	D

Explanation of Responses:

1. These stock options were granted on December 13, 2024 under the 2017 Amended and Restated Performance Incentive Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of five years from the date of grant.

2. The Organization and Compensation Committee of the Board of Directors of the Issuer determined on July 23, 2026 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on July 24, 2026 (subject to remaining time-based vesting requirements).

	Elizabeth Zhang, Attorney-in-Fact	07/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)